Loading stock data…
QTRX
$3.40+0.27 (+8.63%)
Market ClosedLast close May 1
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Quanterix Corporation in the Healthcare sector is trading at $3.40. The stock is currently near its 52-week low of $2.95, remaining 38.2% below its 200-day moving average. Technical signals show neutral RSI of 50 and bullish MACD crossover, explaining why QTRX maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.40
Potential Upside
5%
Whystock Fair Value$3.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Hold
Mean target$5.33+56.9%
Range$4.00 – $7.00
Fundamentals
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Si...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$153.02M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.32
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-36.23%
Volume
Today's trading volume
745,690
Recent News
How The Quanterix (QTRX) Story Is Shifting After The Latest Fair Value Reset
Quanterix is back in focus after analysts reset their fair value estimate from US$7.33 to US$5.33, a cut of about 27% that reframes what they see as a central case for the stock. The latest research links this move directly to a refreshed view of execution risk, with bulls and bears splitting over whether the lower target adds caution or signals deeper concern. As you read on, you will see how these shifting price targets can help you track the evolving story around Quanterix. Analyst Price...
Quanterix (QTRX) Q4 2025 Earnings Call Transcript
Need a quote from a Motley Fool analyst? With me on today's call are Everett Cunningham, Quanterix Corporation President and CEO, and Vandana Sriram, Quanterix Corporation Chief Financial Officer. During the course of today's presentation, we will make forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act.
Quanterix Corporation Q4 2025 Earnings Call Summary
Moby summary of Quanterix Corporation's Q4 2025 earnings call
Quanterix Corp (QTRX) Q4 2025 Earnings Call Highlights: Revenue Surge Amidst Strategic Shifts
Quanterix Corp (QTRX) reports a 25% revenue increase, strategic innovations, and a path to cash flow breakeven by late 2026.
Quanterix Q4 Earnings Call Highlights
Quanterix (NASDAQ:QTRX) reported fourth-quarter 2025 revenue of $43.9 million, up 25% from the prior year and up 7% sequentially, as the company cited a stronger-than-expected quarter driven in part by “pent-up demand” from academic customers. On the company’s earnings call, newly appointed Presiden